Amgen Inc. Submits SEC Filing Reporting Material Corporate Changes

Strategic Insights -

Amgen Inc., a leading biopharmaceutical company, recently submitted a U.S. Securities and Exchange Commission (SEC) filing (Form 8-K) on November 3, 2022, reporting material events and corporate changes. This filing, which includes 16 documents, is available for public review on the SEC's website. As a biotech leader, Amgen's reporting is closely monitored by investors and industry stakeholders.

Key Takeaways:

  • Amgen Inc. submitted a Form 8-K filing to the SEC on November 3, 2022, reporting material corporate changes and events.
  • The filing includes 16 documents, which are available for public review on the SEC's website.
  • A Form 8-K is a "current report" used to report material events or corporate changes of importance to investors or security holders.
  • The SEC filing provides more current information on specified events than would Forms 10-Q or 10-K.
  • The company's contact information, including address and phone number, is listed as ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320, (805)447-1000.
  • The SIC code for Amgen's primary industry is 2836, Biological Products, (No Diagnostic Substances).
  • The SEC file number for this filing is 0000318154-22-000053.

Statistics:

  • One SEC filing (Form 8-K) was submitted by Amgen Inc. on November 3, 2022.
  • The filing contains 16 documents.
  • The SEC file number for this filing is 0000318154-22-000053.
  • Amgen's primary industry is classified under SIC code 2836.

Sources:

  • U.S. Securities and Exchange Commission (SEC) - [www.sec.gov]( http://www.sec.gov )
  • NewsRx - 2022 NOV 23 - Biotech Week - [www.biotechweek.com](http://www.biotechweek.com)